{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-043086","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2021-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.763181+00:00","generated_at":"2026-06-29T16:24:44.818453+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"aTyr Pharma Q2 cash $44.1M; sarcoidosis data readout expected mid-September","bullets":["Cash, equivalents and investments $44.1M as of June 30, 2021; R&D expense $7.7M, G&A $2.8M.","Last patient visit completed in Phase 1b/2a study of ATYR1923 in pulmonary sarcoidosis; data due mid-September 2021.","Kyorin completed Phase 1 study of ATYR1923 in 32 Japanese volunteers; safe, well-tolerated, PK consistent.","Appointed Sara Zaknoen, M.D. to board; received US patent for ATYR1923 lung inflammation methods.","Shares outstanding 16.9M as of Aug 9, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-043086","json":"https://secwatch.observer/filing/0001564590-21-043086.json","markdown":"https://secwatch.observer/filing/0001564590-21-043086.md","text":"https://secwatch.observer/filing/0001564590-21-043086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000156459021043086/0001564590-21-043086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000156459021043086/life-8k_20210810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T16:24:44.818453+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}